Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG.

Clin Cancer Res. 2010 Nov 1;16(21):5260-8. doi: 10.1158/1078-0432.CCR-10-0994. Epub 2010 Sep 16.

2.

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.

Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S.

J Clin Oncol. 2009 Jan 20;27(3):439-45. doi: 10.1200/JCO.2008.17.2742. Epub 2008 Dec 8.

3.

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ.

J Clin Oncol. 2009 Sep 1;27(25):4068-75. doi: 10.1200/JCO.2008.20.5476. Epub 2009 Aug 3.

4.

Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.

Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E.

Eur J Endocrinol. 2012 Nov;167(5):643-50. doi: 10.1530/EJE-12-0405. Epub 2012 Aug 23.

5.

Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.

Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A.

Clin Endocrinol (Oxf). 2013 May;78(5):760-7. doi: 10.1111/cen.12057.

PMID:
23009688
6.

Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.

Mucha SA, Kunert-Radek J, Pomorski L.

Endokrynol Pol. 2006 Jul-Aug;57(4):452-5.

PMID:
17006852
7.

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI.

J Clin Oncol. 2009 Aug 10;27(23):3794-801. doi: 10.1200/JCO.2008.18.7815. Epub 2009 Jun 29.

8.

Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.

Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G.

Nucl Med Commun. 2011 Dec;32(12):1162-8. doi: 10.1097/MNM.0b013e32834bbe09.

PMID:
21946617
9.

¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.

Salaun PY, Campion L, Ansquer C, Frampas E, Mathieu C, Robin P, Bournaud C, Vuillez JP, Taieb D, Rousseau C, Drui D, Mirallié E, Borson-Chazot F, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F.

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1501-10. doi: 10.1007/s00259-014-2772-0. Epub 2014 May 8.

PMID:
24806110
10.

Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.

Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, Bomanji JB.

Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):49-57. doi: 10.1007/s00259-009-1204-z. Epub .

PMID:
19662413
11.

Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.

Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, Fanti S, Gross MD, Al-Nahhas A, Rubello D.

Eur J Surg Oncol. 2010 Apr;36(4):414-21. doi: 10.1016/j.ejso.2010.01.001. Epub 2010 Jan 25.

PMID:
20100647
12.

Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.

Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM.

Cancer. 2008 Jul 1;113(1):48-56. doi: 10.1002/cncr.23515.

13.

Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.

Treglia G, Villani MF, Giordano A, Rufini V.

Endocrine. 2012 Dec;42(3):535-45. doi: 10.1007/s12020-012-9671-6. Epub 2012 Apr 17. Review.

PMID:
22527889
14.

Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.

Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds A, Powles T.

Clin Cancer Res. 2011 Sep 15;17(18):6021-8. doi: 10.1158/1078-0432.CCR-10-3309. Epub 2011 Jul 8.

15.

The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.

Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, Al-Nahhas A, Gross MD.

Eur J Surg Oncol. 2008 May;34(5):581-6. Epub 2007 Sep 24.

PMID:
17892923
16.

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M.

J Clin Oncol. 2010 Feb 10;28(5):767-72. doi: 10.1200/JCO.2009.23.6604. Epub 2010 Jan 11.

17.

Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.

Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schäfers M, Schober O.

Langenbecks Arch Surg. 1998 Apr;383(2):160-3.

PMID:
9641890
18.

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY.

Cancer. 2012 Mar 1;118(5):1252-9. doi: 10.1002/cncr.26440. Epub 2011 Sep 6.

19.

¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I.

Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1373-80. doi: 10.1007/s00259-012-2065-4. Epub 2012 Jun 21.

PMID:
22718304
20.

FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.

Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM.

Cancer Imaging. 2015 Sep 3;15:15. doi: 10.1186/s40644-015-0049-x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk